2022 World Conference on Lung Cancer (ePosters)-EP08.01-027. Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON

EP08.01-027. Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON

Back to course

Pdf Summary

The POSEIDON study investigated the outcomes of patients with metastatic non-small-cell lung cancer (mNSCLC) based on their tumor programmed cell death ligand-1 (PD-L1) expression levels. The study evaluated three treatment options: tremelimumab plus durvalumab and chemotherapy (TDCT), durvalumab plus chemotherapy (DCT), or chemotherapy alone (CT).<br /><br />The addition of tremelimumab to durvalumab and chemotherapy extended clinical benefit to patients with PD-L1-negative mNSCLC. This suggests that targeting both cytotoxic T lymphocyte antigen-4 (CTLA-4) and PD-L1 checkpoints in the immune response is effective in these patients.<br /><br />The improved survival benefit with TDCT was observed in patients with PD-L1 positive tumors as well as PD-L1-negative tumors. This is important because patients with PD-L1-negative tumors often have suboptimal outcomes with current treatment options.<br /><br />Overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) were all improved with TDCT compared to CT in the PD-L1 positive subgroup. However, there was no significant improvement in OS with DCT compared to CT in the PD-L1 negative subgroup.<br /><br />The safety profile of the different treatment options was generally consistent across the PD-L1 expression subgroups.<br /><br />The study highlights the potential benefit of adding tremelimumab to durvalumab and chemotherapy for patients with low or no PD-L1 expression on their tumor cells who have limited treatment options.<br /><br />The results of the study support the use of immunotherapies that target both CTLA-4 and PD-L1 in the treatment of mNSCLC, particularly in patients with PD-L1-negative tumors. These findings have important implications for improving outcomes in patients with hard-to-treat disease.

Asset Subtitle

Edward B. Garon

Meta Tag

Speaker Edward B. Garon

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

POSEIDON study

metastatic non-small-cell lung cancer

PD-L1 expression levels

tremelimumab plus durvalumab

chemotherapy alone

cytotoxic T lymphocyte antigen-4

improved survival benefit

suboptimal outcomes

overall survival

immunotherapies